Pfizer Trispecific Antibody Hits Skin Clearance Endpoint in Phase 2 AD Trial
Pfizer reports its trispecific antibody achieved significant skin clearance in a Phase 2 atopic dermatitis trial, signaling a potential new biologic mechanism beyond the IL-4/IL-13 axis for moderate-…